Arlington Capital Management’s AstraZeneca AZN Stock Holding History

Arlington Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-26,601	Closed	-$2.02M	–	48
2018 Q4	$2.02M	Sell	26,601 -2,686	-9%	-$210K	1.5%	13
2018 Q3	$2.32M	Sell	29,287 -3,823	-12%	-$289K	1.14%	11
2018 Q2	$2.33M	Sell	33,110 -1,580	-5%	-$114K	1.94%	11
2018 Q1	$2.43M	Buy	+34,690	New	+$2.4M	2.53%	12
2015 Q1	–	Sell	-3,953	Closed	-$278K	–	31
2014 Q4	$278K	Buy	+3,953	New	+$283K	0.24%	29

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arlington Capital Management's AZN Position: Q1 2019 in Review

Arlington Capital Management sold out of AstraZeneca (AZN) in Q1 2019, closing a stake of 26,601 shares — an estimated $2.02M sold.

Arlington Capital Management first reported a position in AZN in Q4 2014 and held it in 5 quarters. The position peaked at $2.43M in Q1 2018. 561 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

Arlington Capital Management reported no remaining AstraZeneca position as of Q1 2019 after selling out during the quarter.
Arlington Capital Management sold 26,601 AstraZeneca shares in Q1 2019, an estimated $2.02M.
Arlington Capital Management first reported a position in AstraZeneca in Q4 2014 and held it in 5 quarters.
Arlington Capital Management's AstraZeneca position peaked at $2.43M in Q1 2018.
561 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on Arlington Capital Management's 13F filing for Q1 2019, filed 10 May 2019.